Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Membr Biol
2012 Mar 01;2453:157-63. doi: 10.1007/s00232-012-9424-8.
Show Gene links
Show Anatomy links
Downregulation of the creatine transporter SLC6A8 by JAK2.
Shojaiefard M
,
Hosseinzadeh Z
,
Bhavsar SK
,
Lang F
.
???displayArticle.abstract???
Janus-activated kinase-2 (JAK2) participates in the regulation of the Na⁺-coupled glucose transporter SGLT1 and the Na⁺-coupled amino acid transporter SLC6A19. Concentrative cellular creatine uptake is similarly accomplished by Na⁺-coupled transport. The carrier involved is SLC6A8 (CreaT). The present study thus explored whether JAK2 regulates the activity of SLC6A8. To this end, cRNA encoding SLC6A8 was injected into Xenopus oocytes with or without cRNA encoding wild-type JAK2, constitutively active (V617F)JAK2 or inactive (K882E)JAK2. Electrogenic creatine transport was determined in those oocytes by dual-electrode voltage-clamp experiments. In oocytes injected with cRNA encoding SLC6A8 but not in oocytes injected with water or with cRNA encoding JAK2 alone, addition of 1 mM creatine to the extracellular bath generated an inward current (I (crea)). In SLC6A8 expressing oocytes I (crea) was significantly decreased by coexpression of JAK2 or (V617F)JAK2 but not by coexpression of (K882E)JAK2. According to kinetic analysis, coexpression of JAK2 decreased the maximal transport rate without significantly modifying the affinity of the carrier. In oocytes expressing SLC6A8 and (V617F)JAK2 I (crea) was gradually increased by the JAK2 inhibitor AG490 (40 μM). In SLC6A8 and JAK2 coexpressing oocytes the decline of I (crea) following disruption of carrier insertion with brefeldin A (5 μM) was similar in the absence and presence of JAK2. In conclusion, JAK2 is a novel regulator of the creatine transporter SLC6A8, which downregulates the carrier, presumably by interference with carrier protein insertion into the cell membrane.
Alcaide,
Defining the pathogenicity of creatine deficiency syndrome.
2011, Pubmed
Alcaide,
Defining the pathogenicity of creatine deficiency syndrome.
2011,
Pubmed
Alcaide,
A new case of creatine transporter deficiency associated with mild clinical phenotype and a novel mutation in the SLC6A8 gene.
2010,
Pubmed
Anselm,
Cardiac manifestations in a child with a novel mutation in creatine transporter gene SLC6A8.
2008,
Pubmed
Ardon,
Creatine transporter deficiency in two half-brothers.
2010,
Pubmed
Baskin,
The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.
2010,
Pubmed
Battini,
Mental retardation and verbal dyspraxia in a new patient with de novo creatine transporter (SLC6A8) mutation.
2007,
Pubmed
Battini,
Language disorder with mild intellectual disability in a child affected by a novel mutation of SLC6A8 gene.
2011,
Pubmed
Bhavsar,
Stimulation of the amino acid transporter SLC6A19 by JAK2.
2011,
Pubmed
,
Xenbase
Böhmer,
The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19.
2010,
Pubmed
,
Xenbase
Braissant,
AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review.
2008,
Pubmed
Braissant,
Creatine deficiency syndromes and the importance of creatine synthesis in the brain.
2011,
Pubmed
Braissant,
Dissociation of AGAT, GAMT and SLC6A8 in CNS: relevance to creatine deficiency syndromes.
2010,
Pubmed
Brault,
Muscle creatine uptake and creatine transporter expression in response to creatine supplementation and depletion.
2003,
Pubmed
Brooks,
The growth hormone receptor: mechanism of activation and clinical implications.
2010,
Pubmed
Christie,
Functional insights into the creatine transporter.
2007,
Pubmed
Coaxum,
Epidermal growth factor activates Na(+/)H(+) exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin.
2009,
Pubmed
Dodd,
Cysteine 144 in the third transmembrane domain of the creatine transporter is located close to a substrate-binding site.
2001,
Pubmed
Feng,
Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop.
1997,
Pubmed
Garnovskaya,
Hypertonicity activates Na+/H+ exchange through Janus kinase 2 and calmodulin.
2003,
Pubmed
Gatsios,
Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock.
1998,
Pubmed
Gehring,
Regulation of the glutamate transporter EAAT2 by PIKfyve.
2009,
Pubmed
,
Xenbase
Gong,
Regulation of glucose transport and c-fos and egr-1 expression in cells with mutated or endogenous growth hormone receptors.
1998,
Pubmed
Guimbal,
A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression.
1993,
Pubmed
Hahn,
X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28.
2002,
Pubmed
Handler,
Regulation of the myo-inositol and betaine cotransporters by tonicity.
1996,
Pubmed
Ho,
JAK2 Translocations in hematological malignancies: Review of the literature.
2010,
Pubmed
Hoffmann,
Sensors and signal transduction pathways in vertebrate cell volume regulation.
2006,
Pubmed
Hosseinzadeh,
Stimulation of the glucose carrier SGLT1 by JAK2.
2011,
Pubmed
,
Xenbase
Jensen,
Hybridisation-based resequencing of 17 X-linked intellectual disability genes in 135 patients reveals novel mutations in ATRX, SLC6A8 and PQBP1.
2011,
Pubmed
Kurdi,
JAK redux: a second look at the regulation and role of JAKs in the heart.
2009,
Pubmed
Li,
Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells.
2010,
Pubmed
,
Xenbase
Loike,
Extracellular creatine regulates creatine transport in rat and human muscle cells.
1988,
Pubmed
Longo,
Disorders of creatine transport and metabolism.
2011,
Pubmed
Lopez,
Molecular basis of cytokine receptor activation.
2010,
Pubmed
Mahfouz,
JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
2011,
Pubmed
Mak,
Immunohistochemical localisation of the creatine transporter in the rat brain.
2009,
Pubmed
Mancardi,
Severe epilepsy in X-linked creatine transporter defect (CRTR-D).
2007,
Pubmed
Mellott,
Prenatal choline deficiency increases choline transporter expression in the septum and hippocampus during postnatal development and in adulthood in rats.
2007,
Pubmed
Mercimek-Mahmutoglu,
Treatment of intractable epilepsy in a female with SLC6A8 deficiency.
2010,
Pubmed
Mohamed,
Functional analysis of a novel I71N mutation in the GJB2 gene among Southern Egyptians causing autosomal recessive hearing loss.
2010,
Pubmed
,
Xenbase
Morris,
Recent advances in understanding leptin signaling and leptin resistance.
2009,
Pubmed
Nash,
Cloning, pharmacological characterization, and genomic localization of the human creatine transporter.
1994,
Pubmed
Neubauer,
Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure.
1999,
Pubmed
Oh,
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
2010,
Pubmed
Omerovic,
Growth hormone induces myocardial expression of creatine transporter and decreases plasma levels of IL-1beta in rats during early postinfarct cardiac remodeling.
2003,
Pubmed
Pardanani,
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
2011,
Pubmed
Pasantes-Morales,
Brain volume regulation: osmolytes and aquaporin perspectives.
2010,
Pubmed
Puusepp,
The screening of SLC6A8 deficiency among Estonian families with X-linked mental retardation.
2010,
Pubmed
Rexhepaj,
Stimulation of electrogenic glucose transport by glycogen synthase kinase 3.
2010,
Pubmed
,
Xenbase
Rosenberg,
Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application.
2007,
Pubmed
Salomons,
X-linked creatine transporter defect: an overview.
2003,
Pubmed
Santos,
JAK2 inhibitors: what's the true therapeutic potential?
2011,
Pubmed
Shojaiefard,
Stimulation of the creatine transporter SLC6A8 by the protein kinase mTOR.
2006,
Pubmed
,
Xenbase
Shojaiefard,
Stimulation of the creatine transporter SLC6A8 by the protein kinases SGK1 and SGK3.
2005,
Pubmed
,
Xenbase
Skelton,
Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency.
2011,
Pubmed
Sora,
The cloning and expression of a human creatine transporter.
1994,
Pubmed
Speer,
Creatine transporters: a reappraisal.
2004,
Pubmed
Spivak,
Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
2010,
Pubmed
Stockler,
Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology.
2007,
Pubmed
Strutz-Seebohm,
PIKfyve in the SGK1 mediated regulation of the creatine transporter SLC6A8.
2007,
Pubmed
,
Xenbase
Takenaka,
The canine betaine gamma-amino-n-butyric acid transporter gene: diverse mRNA isoforms are regulated by hypertonicity and are expressed in a tissue-specific manner.
1995,
Pubmed
Tefferi,
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
2010,
Pubmed
Tefferi,
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
2009,
Pubmed
Tran,
Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter.
2000,
Pubmed
,
Xenbase
Uchida,
Molecular cloning of the cDNA for an MDCK cell Na(+)- and Cl(-)-dependent taurine transporter that is regulated by hypertonicity.
1992,
Pubmed
,
Xenbase
van de Kamp,
Clinical features and X-inactivation in females heterozygous for creatine transporter defect.
2011,
Pubmed
Wang,
Cr supplementation decreases tyrosine phosphorylation of the CreaT in skeletal muscle during sepsis.
2002,
Pubmed
Yokota,
Effect of growth hormone on the translocation of GLUT4 and its relation to insulin-like and anti-insulin action.
1998,
Pubmed
